<DOC>
	<DOCNO>NCT01286987</DOCNO>
	<brief_summary>This single-arm , open-label study ass safety , pharmacokinetics , pharmacodynamics , preliminary efficacy talazoparib patient advanced tumor DNA-repair pathway deficiency . There 2 part study : dose escalation phase maximum tolerate dose define , dose expansion phase .</brief_summary>
	<brief_title>Study Talazoparib , PARP Inhibitor , Patients With Advanced Recurrent Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Talazoparib</mesh_term>
	<criteria>Histologically cytologically document , unresectable , locally advanced metastatic solid tumor Must available archive tumor tissue ( formalinfixed paraffinembedded ) [ FFPE ] . 18 year age old . Have measurable disease Response Evaluation Criteria Solid Tumors ( RECIST , v1.1 ) increase CA125 ( ovarian cancer ) PSA ( prostate cancer ) and/or CA 199 ( pancreatic cancer ) . Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 1 . Have adequate organ function Able take oral medication . Willing able provide inform consent . Sexually active patient must willing use acceptable method contraception . Females childbearing potential must negative serum pregnancy test screening . Willing able comply study procedure . Part 2 Dose Expansion Tumor Types : Breast ovarian cancer patient deleterious pathogenic BRCA mutation receive 4 prior regimen metastatic disease . Prostate pancreatic cancer patient deleterious pathogenic BRCA mutation receive 2 prior regimen metastatic disease . Small cell lung cancer ( SCLC ) patient receive one prior regimen SCLC . Ewing 's sarcoma patient receive 3 prior regimen metastatic disease . Part 2 Expansion : Prior treatment PARP inhibitor . Has history central nervous system ( CNS ) metastasis . * Exception : In patient SCLC , history adequately treat brain metastasis require corticosteroids management CNS symptom . Has major surgery within 28 day Cycle 1 , Day 1 . Has active peptic ulcer disease . Active gastrointestinal tract disease malabsorption syndrome . Pregnant breastfeed screen plan become pregnant ( case , either oneself one 's partner ) time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>BRCA1 Protein</keyword>
	<keyword>BRCA2 Protein</keyword>
</DOC>